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Background: The patient population derived from lung cancer
screening programs with low-dose spiral computed tomography
(LDCT) is different from the general population accessing thoracic
surgical services.
Methods: Retrospective review of all surgical cases in the DANTE
trial, a randomized study of lung cancer screening with LDCT.
Patient characteristics, workup, procedures, resections for benign
disease, complications, tumor features, and final outcomes have
been analyzed in the LDCT and in the control arm.
Results: In the LDCT arm, 77 suspicious lesions were surgically
managed in 72 patients. A benign lesion was diagnosed in 17 cases
(22%). Major video-assisted thoracoscopic surgery resection was
carried out in five lung cancer cases (7%) and segmentectomy in 11
(19%). Complete resection was achieved in 93%, and stage I rate
was 73%. Two patients had a local recurrence after open lobectomy,
and three had a resectable new primary. In the control group, 28
patients underwent 31 surgical procedures, in five cases (16%) for
benign lesions. No major video-assisted thoracoscopic surgery re-
sections were carried out. Resectability rate was 88%, and stage I
rate was 52%. Five patients had a local recurrence and two had a
second primary.
Conclusions: Surgery for benign lesions is a relevant issue in
screening-derived patients. Local control may be achieved by min-
imally invasive techniques or segmentectomy; however, developing
the necessary skills requires an effort by the surgical team. Long-
term survivors have a noticeable chance of developing second
primary cancers or resectable recurrences and may benefit from a
second resection.
Key Words: Lung cancer, Screening, Early detection, Low dose
spiral CT, Lobectomy, Video-assisted thoracoscopic surgery, Lim-
ited resections, Second primary.
(J Thorac Oncol. 2011;6: 327–335)
Surgeons involved in lung cancer screening are confrontedwith a special patient population in comparison with
everyday practice, for several reasons. A relevant proportion
of screened subjects present with undetermined pulmonary
nodules, but only a few of these will be genuine lung cancers.
Most tumors detected by low-dose spiral CT (LDCT) are
small, stage I, and resectable,1–11 Table 1. As the prognosis of
screening-detected lung cancer is far better than usual, be-
cause of early diagnosis and possibly due of a quota of
relatively unaggressive tumors, a few patients may have a
chance to develop second primary cancers or resectable
recurrences.
Despite hundreds of publications addressing lung can-
cer screening in the literature, there is only one published
study specifically dealing with the surgical aspects and im-
plications of early detection of lung cancer with spiral CT.12
We herein summarize the surgical management expe-
rience in the setting of a randomized trial of lung cancer early
detection with spiral CT and discuss results in the screening
and the control arm in the light of available data from other
current screening trials.
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PATIENTS AND METHODS
A retrospective review was performed of all surgical
cases and procedures carried out from March 2001 to Sep-
tember 30, 2009, in the DANTE trial, a randomized study of
lung cancer screening with LDCT versus annual clinical
review that enrolled 2472 male subjects at high risk (1276
LDCT and 1196 controls). The research was conducted by
the Humanitas Hospital, Milan, Italy. Two centers of the
same hospital network, the Humanitas-Gavazzeni Hospital in
Bergamo and the Humanitas Oncology Center in Catania,
enrolled subjects for the trial during the last year of accrual.
The trial methodology has already been published,13 and it is
briefly outlined in the Appendix.
Information was collected on patient demographics,
date of actual detection and radiologic aspect of the lesions,
subsequent workup, surgical procedures, and follow-up. Su-
perficial node or subcutaneous biopsies were not included.
Workup information included the results of antibiotic trial,
repeat LDCT, positron emission tomography (PET) scan if
available, and preoperative invasive procedures. Information
on surgical procedures included reasons for surgery, whether
minimally invasive or open, type of thoracotomy, type and
volume of resection, extent of lymphadenectomy, and post-
operative course and complications. Histology and pathologic
stage of tumors, and any induction or adjuvant therapies were
also reported. Postoperative complications were graded ac-
cording to Seely et al.14
The final stage of resected tumors was defined accord-
ing to the 2009 American Joint Committee on Cancer Staging
System.15 New primary cancers were defined according to the
criteria of Martini and Melamed.16
Management Principles
Lesion diameter, the aspect of its margins and its
density (e.g., solid versus focal ground-glass lesion), no
regression after antibiotics, nodule growth, the appearance of
a solid component in a ground-glass lesion, and the results of
PET scan and CT-guided core biopsy were taken into account
before proceeding to surgery (Appendix).
In the case of a newly detected nodule during subse-
quent screening rounds, the previous scans were reviewed in
the first place to ascertain whether it was truly a new lesion or
a preexisting nodule that had been missed and if so whether
the lesion had progressed.
If the lesion was a new one, antibiotics and repeat
high-resolution follow-up CT of the lesion were usually
recommended before PET scan, percutaneous biopsy, or
video-assisted thoracoscopic surgery (VATS).
Preoperative flexible bronchoscopy under local anes-
thesia was routinely carried out on patients with lung cancer
as a staging procedure and to exclude endobronchial second
primaries.
Mediastinoscopy was carried out if PET scan showed
positive mediastinal nodes and if neoadjuvant chemotherapy
was a possibility.
The usual surgical approach in the Milan center was
lateral muscle sparing thoracotomy. Left lower lobectomy, in-
ferior apical segmentectomy, and tumors adhering to the poste-
rior mediastinum or chest wall were often approached through a
posterior muscle sparing or posterolateral thoracotomy.
In Bergamo and Catania, the standard approach was a
posterolateral thoracotomy, which was mostly adopted in
nonparticipating centers.
Lobe-specific mediastinal lymphadenectomy17 was
often carried out on patients with small peripheral tumors
instead of systematic mediastinal dissection if the preop-
erative PET scan of the mediastinum was negative. Nodal
sampling or no mediastinal lymphadenectomy were re-
served for patients with focal ground-glass lesions show-
ing no or a minor solid component and for patients with
relevant comorbidities.
Data Analysis and Statistical Methods
Data were expressed as number and percentage, mean
and 95% confidence interval (CI), or median (range) when
appropriate. A limited comparison with procedures in the
control arm of the trial was also carried out.
TABLE 1. Results of Selected Lung Cancer Screening Trials
Study Trial Type No. Age No. of Rounds % Recall Total LC % LC % Stage I No. of Surgery % Benign
Shinshu Uni1 O 5483 40–74 3 10 63 1.1 81 72 22
Hitachi2 O 7965 50–69 2 8.9 40 0.5 78 57 30
Mayo Clinic3 O 1520 50–85 5 37 66 4.5 55 70 18a
I-ELCAP4 O 31,567 40–85 2 13 484 1.5 85 — 8b
PLuSS5 O 3642 50–79 2 31 80 2.2 50 88 37
Milan Uni6 O 5189 50 2 11 92 1.8 66 104 14
Toronto7 O 3352 50–83 2 18 65 1.9 65 48 18b
LSS8 R 1660 55–74 2 — 36 2.3 48 30 45b
DLCST9 R 2052 50–70 0 8.7 17 0.8 53 13 15
NELSON10 R 7757 50–74 2 27 144 1.86 67 — 27
ITALUNG11 R 1406 55–69 0 30 20 1.5 50 17 5
a Data combined with Ref. 12.
b All invasive procedures.
O, observational; R, randomized; no., subjects in the LDCT screening arm only; total LC, all cases detected throughout the study period, including interval cases.
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Proportion comparisons between groups were made by
the 2 test, using the Fisher’s exact test if necessary. For age
differences and tumor diameters in either group, the two-
sample t test was used. Time from detection to treatment and
follow-up times were compared by the Wilcoxon test. Pos-
tresection survival was calculated by the method of Kaplan
and Meier. Postoperative deaths were considered as deaths
from lung cancer.
RESULTS
Surgery in the LDCT Arm
As of September 2009, 449 participants were detected
with abnormal findings in their chest CT, and 349 (27%) were
recalled for further assessment. Of these, 113 patients initially
received an antibiotic trial, after which 13 lesions progressed
(11 cancers), 65 remained stable (19 cancers), and 35 re-
gressed. Patient characteristics, preoperative invasive proce-
dures, and thoracic surgical operations are summarized in
Tables 2 and 3.
Seventy-seven suspicious lesions were surgically man-
aged in 72 patients. The lesions had been detected by a
baseline LDCT in 36 of 77 (46%) instances, by a follow-up
CT in 34, and for other reasons in seven cases. They were
retrospectively visible in 12 cases, in 10 of which lung cancer
was eventually diagnosed.
Three patients had isolated mediastinal lymphadenop-
athy, and three had a pleural effusion; a single pulmonary
lesion was visible in the CT scan in 64 instances, multiple
ipsilateral lesions in six, bilateral lesions in one, and no tumor
was visible in one patient, whose lesion was detected by
baseline sputum examination.
Median observation time from detection to surgery was
3 (0–74) months.
Preoperative flexible bronchoscopy detected an endo-
bronchial second primary in two patients.
Three mediastinoscopies were carried out for enlarged,
PET-positive lymph nodes as the only abnormal finding on
LDCT. Tuberculosis was diagnosed in one and chronic
lymphadenitis in two. In three more patients with established
lung cancer, mediastinoscopy was carried out for staging
purposes.
Three patients had a VATS biopsy for persistent pleural
effusions (one had stage IV lung cancer and two had malig-
nant pleural mesothelioma), and seven more patients had a
VATS lung biopsy for benign nodules.
Six open wedge resections were carried out for inflam-
matory nodules and one segmentectomy for atypical adeno-
matous hyperplasia, but no lobectomies or pneumonectomies
were carried out for benign lesions. Overall, a benign lesion
was diagnosed in 17 of 77 (22%) surgical procedures carried
out for possible lung cancer. Three patients underwent VATS
procedures against the recommendations of the trial team.
Most surgical procedures for benign disease were car-
ried out during the first 3 years of the study: in 12 of 131
(9.1%) instances of abnormal LDCT findings before Decem-
ber 31, 2004, and in 5 of 218 (2.3%) afterward (p  0.008).
Five patients underwent a second resection (three left
completion pneumonectomies, one contralateral segmentec-
tomy, and one wedge resection) after successful surgery for lung
carcinoma: three had metachronous lung cancer, one had a
resectable ipsilateral recurrence, and one had a mycetoma.
Complete lung cancer resection was attempted in 56 of
58 cases, and it was macroscopically achieved in 55. The
resection margin was microscopically involved in one patient
who underwent bilobectomy after induction chemotherapy.
Mediastinal lymphadenectomy was systematic in 17 of
55 cases, lobe-specific in 21, sampling only in 13, and it was
TABLE 2. Patients’ Characteristics and Invasive Procedures
LDCT (%) Control (%) p
No. of subjects 1276 (100) 1196 (100)
Mean age at enrolment
95% CI
64.3 64.0–64.7 64.6 64.3–64.9
Mean age at detection
95% CI
67.5 66.6–68.3 68.5 66.3–70.7
Invasive proceduresa
For any reason 134 (10.5) 54 (4.5) 0.001
After screening LDCT 106 (8.3) —
CT-guided core biopsy 36 14
Bronchoscopy 31 13
Surgical proceduresb 77 (6.0) 31 (2.6) 0.001
Median time to surgery (mo) 3 (0–74) 2 (0–13) 0.006
Reasons for surgery
Mediastinal nodes 3 —
Pleural effusion 3 3
Focal GGOs 17 1
Nodules 47 17
Central mass 6 8
Normal CT scanc 1 —
Missing data — 2
Surgery in nonparticipating
hospitals
8 (10.4) 11 (35.4) 0.002
Surgical approachd
Lateral-muscle sparing 40 (56) 12 (43)
Posterior or posterolateral 18 (25) 11 (39)
VATS resection 12 (17) 2 (7)
Unknown 1 (1) 3 (11)
Lymphadenectomye
Systematic 17 (31) 11 (48)
Lobe specific 21 (38) 7 (30)
Sampling only or none 17 (31) 2 (9)
Unknown — 3 (13)
Median no. of examined
lymph nodes
9 (0–33) 11 (0–18)
Median duration of surgery
(min)
134 (83–328) 159 (75–215)
Median postresection FU (mo) 25 (0–102) 31 (1–81)
a Includes bronchoscopy, CT-guided percutaneous biopsy, or any surgery. Staging
procedures not shown.
b Five LDCT and one control patients underwent 1 lung resection for local
recurrence or suspected new primary.
c An endobronchial tumor in the right upper lobe was detected by baseline sputum
examination.
d Excluding mediastinoscopies and VATS pleural biopsies.
e Fifty-five LDCT cases and 23 controls in whom macroscopically complete
resection was achieved.
LDCT, low-dose spiral CT; GGOs, ground-glass opacities; CT, computed tomog-
raphy; VATS, video-assisted thoracoscopic surgery; CI, confidence interval.
Journal of Thoracic Oncology • Volume 6, Number 2, February 2011 Surgical Procedures in the DANTE Trial
Copyright © 2011 by the International Association for the Study of Lung Cancer 329
TA
B
LE
3.
Su
rg
er
y
fo
r
Lu
ng
C
an
ce
r
an
d
Be
ni
gn
Le
si
on
s:
C
om
p
lic
at
io
ns
an
d
Fa
ilu
re
s
L
D
C
T
C
on
tr
ol
A
ll
B
en
ig
n
(%
)
C
om
pl
ic
at
io
ns
F
ai
lu
re
sa
A
ll
B
en
ig
n
(%
)
C
om
pl
ic
at
io
ns
F
ai
lu
re
sa
M
ed
ia
st
in
os
co
py
b
3
3
R
ec
ur
re
nt
ne
rv
e
le
si
on
1
V
A
T
S
fo
r
pl
eu
ra
l
bi
op
sy
3c
—
—
3
1
V
A
T
S
w
ed
ge
re
se
ct
io
n
7
7
—
2d
1
O
pe
n
w
ed
ge
re
se
ct
io
n
8
6
A
ir
le
ak
3
an
d
ca
rd
ia
c
1
L
oc
al
re
cu
rr
en
ce
1
2
1
C
ar
di
ac
1
L
oc
al
re
cu
rr
en
ce
1
V
A
T
S
se
gm
en
te
ct
om
y
1
—
—
O
pe
n
se
gm
en
te
ct
om
y
12
1e
A
te
le
ct
as
is
1,
lo
be
re
m
na
nt
in
fa
rc
ti
on
2,
he
m
or
rh
ag
e
1,
an
d
se
ve
re
pn
eu
m
on
ia
1
1
1
V
A
T
S
lo
be
ct
om
y
4
—
A
ir
le
ak
,
in
fe
ct
io
n
1
S
ec
on
d
pr
im
ar
y
1
L
ob
ec
to
m
y/
bi
lo
be
ct
om
y
27
—
A
ir
le
ak
1,
at
el
ec
ta
si
s
1,
ai
r
le
ak
,
in
fe
ct
io
n
1,
he
m
or
rh
ag
e
1,
an
d
su
dd
en
ca
rd
ia
c
de
at
hf
1
L
oc
al
re
cu
rr
en
ce
1,
se
co
nd
pr
im
ar
y
2,
an
d
di
st
an
t
m
et
a
3
16
A
ir
le
ak
2
an
d
ca
rd
ia
c
1
L
oc
al
re
cu
rr
en
ce
4,
se
co
nd
pr
im
ar
y
2,
an
d
di
st
an
t
m
et
a
1
S
le
ev
e
lo
be
ct
om
y
3
—
A
te
le
ct
as
is
1
an
d
su
tu
re
-l
in
e
fa
il
ur
ef
1
2
P
ne
um
on
ec
to
m
y
4
—
A
R
D
S
f
1
an
d
re
cu
rr
en
t
ne
rv
e
le
si
on
1
D
is
ta
nt
m
et
a
2
2
S
ut
ur
e-
li
ne
fa
il
ur
ef
1
D
is
ta
nt
m
et
a
1
C
om
pl
et
io
n
pn
eu
m
o
3
—
M
il
d
bl
ee
di
ng
1
an
d
pr
ol
on
ge
d
fe
ve
r
1
2
C
hy
lo
th
or
ax
1
E
xp
lo
ra
to
ry
th
or
ac
ot
om
y
2
1
1
T
ot
al
77
17
(2
2)
31
5
(1
6)
a
T
re
at
m
en
t
fa
il
ur
es
af
te
r
m
ac
ro
sc
op
ic
al
ly
co
m
pl
et
e
lu
ng
ca
nc
er
re
se
ct
io
n.
b
M
ed
ia
st
in
os
co
pi
es
ca
rr
ie
d
ou
t
fo
r
st
ag
in
g
pu
rp
os
es
no
t
sh
ow
n.
c
T
w
o
pa
ti
en
ts
di
ag
no
se
d
w
it
h
m
al
ig
na
nt
pl
eu
ra
l
m
es
ot
he
li
om
a.
d
O
ne
pa
ti
en
t
di
ag
no
se
d
w
it
h
ly
m
ph
om
a.
e
O
ne
pa
ti
en
t
di
ag
no
se
d
w
it
h
at
yp
ic
al
ad
en
om
at
ou
s
hy
pe
rp
la
si
a.
f
P
at
ie
nt
di
ed
of
co
m
pl
ic
at
io
ns
.
L
D
C
T
,
lo
w
-d
os
e
sp
ir
al
C
T
pa
ti
en
ts
;
C
T
R
L
,
co
nt
ro
l
pa
ti
en
ts
;
A
R
D
S
,
ad
ul
t
re
sp
ir
at
or
y
di
st
re
ss
sy
nd
ro
m
e;
C
T
,
co
m
pu
te
d
to
m
og
ra
ph
y;
V
A
T
S
,
vi
de
o-
as
si
st
ed
th
or
ac
os
co
pi
c
su
rg
er
y.
Infante et al. Journal of Thoracic Oncology • Volume 6, Number 2, February 2011
Copyright © 2011 by the International Association for the Study of Lung Cancer330
not carried out in four (one VATS segmentectomy, one
VATS lobectomy, one open lobectomy, all for focal ground
glass opacities (GGOs), and one wedge resection).
There were two exploratory thoracotomies: in one case,
palliative pleurectomy was intentionally carried out in an-
other hospital, and in the second case, lobectomy was at-
tempted, but pneumonectomy was required that would have
not been tolerated.
Postoperative complications occurred in 22 cases
(28.6%) and were grade III or higher in nine. Unfortunately,
three patients died postoperatively (4% mortality rate): one of
a bronchopleural fistula after a sleeve lobectomy, one of
respiratory distress syndrome after right pneumonectomy,
and the last one experienced sudden cardiac death 8 days after
a lobectomy (Table 3).
The pathologic stage and histologic types of all 58
tumors are presented in Table 4.
Median postresection follow-up was 25 (0–102)
months. Two patients recurred locally: one in the remaining
lobe after left upper lobectomy, and he was alive and disease
free 24 months after completion pneumonectomy. The sec-
ond patient recurred locally after a wedge resection and
received radiotherapy; he was alive with disease after 36
months.
Three patients had a new primary cancer: two under-
went completion pneumonectomy and one a contralateral
segmentectomy. All of them were alive and disease free 30 to
95 months after the first resection and 12 to 14 months after
the second one.
As of September 2009, 11 patients had died of lung
cancer and four of other causes. Actuarial postresection
5-year survival in this group was 80% (95% CI: 64–89).
During the same period, seven patients underwent in-
tentional thoracic procedures for pulmonary or mediastinal
lesions other than lung cancer detected by LDCT, and two
patients underwent nonthoracic procedures for screening-
detected lesions in the upper abdomen.
Surgery in the Control Arm
In this group, 28 patients underwent 31 surgical proce-
dures for suspicious lesions (Tables 2 and 3). The mean age
at the time of lesion detection was not significantly different
from the LDCT group patients.
Investigation leading to a surgical procedure was initi-
ated for several reasons: an abnormal chest radiograph (ad-
ministered per protocol on enrolment) in 10 cases, symptoms
in eight cases, abnormal physical findings at annual clinical
review in two, CT scan administered due to patient misallo-
cation in one case, unrelated medical conditions in six, and
follow-up CT after resection in two cases, in the same one
patient.
For the last two patients, both operated on in nonpar-
ticipating centers, such information could not be retrieved.
Lung cancer was diagnosed in 25 cases, lymphoma in
one, and a benign lesion in five (16%). In two cases, the
procedure was carried out against our recommendations.
Control patients had a relative risk of 0.76 of undergo-
ing surgery for a benign lesion compared with LDCT group
patients (p  0.410) and were more likely to undergo surgery
in nonparticipating centers than screening-arm patients (p 
0.002). Complete lung cancer resection was attempted in 23
of 25 cases and achieved in all.
No major VATS resections were carried out for lung
cancer, and only one segmentectomy, but for benign dis-
ease in another hospital. Six patients experienced postop-
erative complications (19%) that were grade III or higher
in two. There was one postoperative death due to bron-
chopleural fistula and adult respiratory distress syndrome
after pneumonectomy (3% mortality rate). The overall
complication rate was not significantly different between
the two groups (p  0.467).
Local recurrences were observed more often after lung
cancer resection in this group (Table 3): after 5 of 23 versus
2 of 55 resections in the LDCT arm (p  0.021).
One patient underwent completion pneumonectomy for
local recurrence, and one underwent metachronous lobec-
tomy for new primary cancer and then completion pneumo-
nectomy 1 year later for local recurrence. Both were alive and
disease free after 12 and 48 months since the last resection.
Mean tumor diameter was higher, and there were fewer
patients with pathologic stage IA disease and less bronchi-
oloalveolar or mixed-type adenocarcinomas (Table 4).
TABLE 4. Characteristics of Lung Cancers
Spiral CT
No. (%)
Control
No. (%) p
Peripheral lesion 25 mm 43 (74) 7 (28) 0.001
Stageb
IA 32 5 0.004
IB 9 8
All stage I 41 (71) 13 (52)
IIA 4 2
IIB 3 4
IIIA 6 3
IIIB–IV 4 2
Unknown — 1
All stages II–IV 17 (29) 12 (48)
Histology
Adeno 18 (31) 8 (33)
Adeno/BACc 17 (29) 1 (4) 0.007
Squamous 16 (27) 12 (44)
Large cell 1 1
Neuroendocrine 2 —
NSCLC NAS 1 1
Other 3 2
Total 58 (100) 25 (100)
Mean tumor size (95% CI)a 19.5 (16.1–22.9) 35.7 (25.8–45.7) 0.001
a Maximum diameter measured on resected specimen expressed in millimeters.
b Two stage IIIA N2 patients were down-staged to IA and IIA after induction
chemotherapy in the LDCT group. One stage IIIA N2 patient was down-staged to stage
IB after induction chemotherapy in the control group.
c Includes 10 mixed-type adenocarcinomas and seven pure bronchioloalveolar
carcinomas (BAC) in the LDCT arm, one pure BAC in control arm.
CT, computed tomography; CI, confidence interval; NSCLC, non-small cell lung
cancer.
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As of September 2009, 10 patients had died of lung
cancer and two of other causes. Actuarial postresection
5-year survival was 52% (95% CI: 28–71%). During the
same period, one patient underwent intentional VATS
thymectomy for thymoma.
DISCUSSION
All surgeons involved in cancer treatment pursue ap-
propriate patient selection, minimization of surgical trauma,
and maximization of local control, but those involved in
screening programs have to adapt their strategies to a special
patient population.
In all lung cancer screening programs with LDCT
including ours, the prevalence of participants with unde-
termined pulmonary nodules was high, with only a fraction
harboring genuine lung cancer. In consequence, a variable
proportion of surgical procedures for benign lesions have
been carried out in every modern lung cancer screening
study, regardless of the evaluation protocols in use (Table 1).
In this study, 17 of 77 (22%) surgical procedures in the
LDCT arm were unintentionally carried out in patients with-
out malignancy, and seven (9%) required a thoracotomy. The
majority of surgical procedures for benign lesions were car-
ried out during the first 3 years of our study.
At that time, in the absence of a reliable noninvasive
test, VATS biopsies were administered more liberally; the
VATS procedure had to be converted to an open wedge
resection in four cases because of adhesions or inability to
locate the nodule. Eventually, negative surgical biopsies de-
creased after the introduction of antibiotic trial, PET scan,
and CT-guided core biopsy in our workup protocol.18,19
Specific expertise in managing screening-derived cases is
clearly of some importance: surgical procedures for benign
lesions are in fact more likely, often against the recommen-
dations of the trial team, when screening-detected pulmonary
lesions are eventually managed by surgeons uninvolved in the
screening program.6,8
In contrast with those ordinarily seen in routine clinical
practice, most cancers detected by LDCT are small, periph-
eral, stage I, and resectable (Table 1). This surgical series is
no exception in that 71% cases in the LDCT group were stage
I. In addition, for several reasons, they were less likely to
recur locally after curative resection compared with control
arm cases.
Minimization of surgical trauma and local control
may therefore be pursued in this patient population by
minimally invasive surgery and tissue-sparing resections,
depending on the expertise and attitude of the surgical
team. VATS lobectomy may be as effective and safe as
open surgery for early-stage lung cancer, and it is rapidly
gaining popularity.20,21 In the Danish Lung Screening
Trial, 83% of major resections were carried out by VATS
(J.H. Pedersen, Department of Thoracic Surgery, Rigshos-
pitalet, University of Copenhagen, Copenhagen, Denmark,
personal communication), whereas in our study, only four
VATS lobectomies and one segmentectomy were carried
out, all on patients with small peripheral tumors or focal
ground-glass lesions.
Although lobectomy has been the standard of care since
1995,22 the role of sublobar resections is being reconsidered
because respiratory function is better preserved by segmen-
tectomy than lobectomy, and because smaller tumors and
some forms of relatively unaggressive cancers detected by
LDCT may be adequately treated by a wedge resection or
segmentectomy. For smaller tumors (2 cm), survival results
with segmentectomy, but not with wedge resection, may be
the same as with lobectomy.23,24
Proportions between lobectomies and lesser resections
vary widely among different centers.6,10,12 As we pursue
“radical” surgery, we have mostly performed lobectomies but
electively performed a segmentectomy (which allows for
removal of local lymphatics) in 19% of the cases, in patients
with small peripheral solid tumors and reduced respiratory
function, and/or with focal GGOs. Only two patients with
lung cancer (3%) underwent a wedge resection by necessity.
Screening-detected patients are expected to achieve
high 5-year survival rates after resection and have a higher
chance to develop second primary cancers or resectable
recurrences. Recently published data show that approxi-
mately 1.5% of all lung cancer cases develop metachronous
lung cancer.25 In surgical series, this percentage may be
increased due to selection. In this study, three operable new
cancers and one resectable recurrence were observed in 52
patients after the first complete resection (Figure 1), and two
patients had synchronous cancers. Overall, 7% underwent a
second resection, however, in one case for a mycetoma
mimicking second primary cancer. The results of the second
resection have been so far rewarding.
The level of medical attention in control patients was
indeed higher than in the normal population; this is an
intrinsic limitation of all controlled trials.
On the other side, subjects in both arms were compa-
rable in their risk of undergoing invasive procedures (except
for the LDCT screening factor), and the information we were
able to obtain about surgical procedures in the control arm
was greater than we would have obtained otherwise.
In this latter group of patients, fewer procedures for
benign disease were carried out, in agreement with the fact
that LDCT screening mostly detects innocent nodules that
may be difficult to differentiate from early lung cancer and
that would otherwise go unnoticed. The longer average time
spent for assessing LDCT patients before proceeding to
surgery reflects such difficulty (Table 2). No major VATS
resections for lung cancer were performed, mainly because
only very few patients in the control group had suitable small
peripheral nodules or focal ground-glass lesions (Table 4).
Control arm patients were also more likely to undergo sur-
gery in nonparticipating centers.
Although early disease may be less difficult to treat,
morbidity and mortality are never negligible after thoracic
operations.14,26 Moreover, developing VATS surgery and
segmentectomy skills actually requires a learning curve27–29:
three segmentectomy patients needed reoperation, one due to
bleeding from the staple line and two because of venous
infarction of the lingula after lingula sparing left upper
lobectomy (Figure 2). One VATS lobectomy patient instead
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experienced prolonged air leak and pleural sepsis. Postoper-
ative mortality was unfortunately higher than we expected.
All patients who died had been judged to be technically
operable and resectable, but all had central tumors, and stage
IIA or higher disease. Two had undergone a pneumonectomy
and two of them had comorbid conditions that posed them at
higher surgical risk.
In conclusion, despite sophisticated workup protocols,
surgery for benign lesions still remains an issue in screening-
detected patients; it can be reduced if surgeons are directly
involved in the early detection program. Screening-detected
cases are often good candidates for segmentectomy and
VATS lobectomy, which allow for local control with a
limited loss of function and may offer the same chances of
cure as traditional open lobectomy; however, developing the
necessary skills requires an effort by the surgical team. In
long-term survivors, second primary lung cancer and resect-
able recurrences may develop with noticeable frequency, and
redo procedures, although sometimes challenging, may offer
a second chance of cure.
High survival rates after resection had been reported
previously in patients with screening-detected lung cancer1,4;
however, it should be remembered that 5-year survival is not
an appropriate measure of the efficacy of screening in reduc-
ing lung cancer mortality.30
The net balance between risks (including surgical mor-
tality) and benefits of screening for lung cancer with spiral
CT needs yet to be determined through the ongoing random-
ized trials.31,32
APPENDIX
Information on the detected lesions included modality
of detection (i.e., baseline or follow-up LDCT and other
reasons), number, location, and radiologic characteristics in-
cluding size (as measured with electronic calipers), shape,
margins, and density (i.e., solid, part-solid, or nonsolid focal
ground-glass lesions).
The date of detection was the day the lesion was
actually reported for the first time, even if visible in
retrospect.
Information on surgical procedures included reasons
for surgery (suspected lung cancer, other condition known
before operation, or complications), minimally invasive or
open surgery, type of thoracotomy, type and volume of
resection if applicable, extent of lymphadenectomy and num-
ber of examined lymph nodes, histology and pathologic stage
of tumors, postoperative complications, date of discharge,
and any induction or adjuvant therapy.
DANTE TRIAL METHODOLOGY IN BRIEF
DANTE is a prospective randomized controlled trial of
lung cancer screening with LDCT versus annual clinical
review. Five screening rounds were planned.13
Baseline Assessment
Patients were requested to fill in a detailed question-
naire formulated in layperson’s terms about their occupa-
tional history, smoking history, and medical history.
FIGURE 1. Resectable ipsilateral
recurrence of stage IA adenocarci-
noma with bronchioloalveolar fea-
tures 3 years after left upper lobec-
tomy. A, preoperative computed
tomography (CT) scan of primary
tumor (arrow). B, CT scan showing
multifocal recurrent adenocarci-
noma in the remaining lobe (ar-
rows). The patient underwent com-
pletion pneumonectomy, and he
was disease free and well 24
months after the second resection.
FIGURE 2. Segmentectomy (lingula
sparing left upper lobectomy) for a
malignant ground-glass lesion (stage IA
adenocarcinoma with bronchioloalveo-
lar features). A, Preoperative computed
tomography (CT) scan of tumor (ar-
row). B, CT scan showing consolidation
of the lobe remnant on postoperative
day 2 (arrow). The patient underwent
completion lobectomy, and he was
discharged on postoperative day 6, in
good condition. Histologic examination
showed venous infarction of the lingula
due to kinking of its veins.
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Symptoms and signs were investigated by the physician
through a structured medical interview, followed by a com-
plete physical examination.
All participants received a baseline, once-only chest
x-ray examination. Sputum cytology examination and the
search for a panel of molecular markers were also carried out
once only on all participants on accrual.
Subjects in the spiral CT group also received their first
screening CT scan immediately thereafter.
Annual Clinical Review
Every year, all subjects in both arms undergo clinical
review.
Smoking habits, recent medical history, and new symp-
toms and signs since last contact are assessed through a
structured medical interview, and a complete physical exam-
ination, focused toward signs and symptoms of lung cancer or
extrapulmonary neoplasia.
Screening arm patients underwent a new spiral CT
irrespective of the interview outcome or physical findings.
Control arm patients do not undergo any further eval-
uation if the interview and physical findings are normal or
consistent with their previous clinical condition.
Low-Dose CT Scan Protocol
Spiral CT images of the whole lungs are obtained
during maximal inspiration at the end of a single breath hold
using a single-slice scanner with low-dose setting (140 kvp,
40 mA) and reconstructed in overlapping contiguous 5 mm
increments, 1.25 pitch, with a high-resolution bone algorithm
(width 1700 and level 600).
Two experienced chest radiologists read the images
independently, and a consensus reading is obtained with the
participation of the local coordinator in the case of a disagree-
ment. Both separate readings and the final consensus are
documented.
Interpretation of Chest Radiographs
CXR results are considered positive if showing a non-
calcified lung shadow, a hilar mass, an enlargement of the
mediastinum, pleural effusion or thickening, or lytic bone
lesions.
Interpretation of LDCT Scans
LDCT results are considered positive if they show
abnormalities noncalcified pulmonary nodules or lesions sug-
gestive of malignancy, such as hilar masses, focal GGOs,
major atelectasis, endobronchial lesions, mediastinal adenop-
athy, pleural effusion, or pleural masses.
Significant abnormalities not suggestive of lung malig-
nancy but requiring further evaluation are reported as well.
Directives for Further Diagnostic Workup of
Pulmonary Lesions Found on LDCT
If the lesion shows benign calcifications on high-reso-
lution computed tomography (HRCT), or regresses after
antibiotic trial, the patient is scheduled for a new CT scan
after 1 year.
In all other cases, investigation follows based on the
size and aspect of the nodule.
If the lesion is smooth and less than 10 mm in size, the
patient is followed by LDCT at 3, 6, and 12 months; if no
change occurs, follow-up after 1 year.
Nonsmooth lesion smaller than 6 mm:
Follow-up by LDCT at 3, 6, and 12 months, if no change
occurs, follow-up after 1 year.
Nonsmooth lesion 6 mm but 10 mm:
Oral antibiotics and new HRCT after 6 to 8 weeks. If no
regression occurs, evaluation on a case-by-case basis as to
the opportunity to follow the lesion or to perform invasive
procedures to obtain a tissue diagnosis (bronchoscopy,
percutaneous fine-needle or core biopsy, or VATS).
Lesion 10 mm but 20 mm:
Oral antibiotics and new HRCT after 6 to 8 weeks. If no
regression occurs, PET scan is recommended. If the PET is
positive, a tissue diagnosis is sought. If the PET scan is
negative, close follow-up is preferentially chosen.
Lesion 20 mm:
Discretional oral antibiotics and new HRCT or standard
contrast-enhanced CT, and PET scan. If the PET is posi-
tive, a tissue diagnosis is sought. If the PET scan is
negative, close follow-up is preferentially chosen.
Focal ground glass opacities:
Oral antibiotics and new HRCT after 6 to 8 weeks. Evalua-
tion on a case-by-case basis as to the opportunity to follow
the lesion or to obtain a tissue-diagnosis based on the size,
number of lesions, location, and ratio of any solid versus
nonsolid component.
The workup protocol is not rigid and may be adjusted on the
basis of the personal preferences, experience, and availability
of facilities.
End Point Ascertainment
A patient’s death may be notified by any person in close
relationship with the deceased participant or by the family
physician, either spontaneously or when the subject is invited
for the annual review.
Copies of any medical records concerning the underly-
ing diagnosis or death cause are requested from the family or
the hospital where the patient was admitted last.
If no hospital record is available, written information is
sought from the family doctor. Linkage with the electronic
database of the local health registries will be completed at the
end of the observation period for all participants.
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